Johnson Investment Counsel Inc. Sells 507 Shares of Boston Scientific Corporation $BSX

Johnson Investment Counsel Inc. cut its position in Boston Scientific Corporation (NYSE:BSX) by 6.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 7,922 shares of the medical equipment provider’s stock after selling 507 shares during the period. Johnson Investment Counsel Inc.’s holdings in Boston Scientific were worth $851,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after purchasing an additional 3,745 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its holdings in shares of Boston Scientific by 8.1% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,163 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 388 shares in the last quarter. Mission Wealth Management LP bought a new position in shares of Boston Scientific in the first quarter valued at approximately $217,000. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Boston Scientific by 37.8% in the first quarter. Janney Montgomery Scott LLC now owns 285,463 shares of the medical equipment provider’s stock valued at $28,798,000 after purchasing an additional 78,301 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock valued at $17,972,457. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BSX shares. Leerink Partners lifted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. BTIG Research lifted their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. UBS Group boosted their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Finally, Barclays lifted their price target on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific has an average rating of “Buy” and an average target price of $120.71.

Boston Scientific Stock Up 1.4%

BSX stock opened at $96.26 on Wednesday. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The business’s 50 day moving average price is $101.58 and its two-hundred day moving average price is $101.80. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market capitalization of $142.63 billion, a price-to-earnings ratio of 57.30, a price-to-earnings-growth ratio of 2.29 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.